Cas:765880-61-3 6-chloro-3,4-dihydro-2H-chromen-4-amine manufacturer & supplier

Chemical Name:6-chloro-3,4-dihydro-2H-chromen-4-amine

CAS.NO:765880-61-3

Synonyms:4-amino-6-chlorochroman;6-CHLOROCHROMANE-4-YLAMINE;6-CHLORO-CHROMAN-4-YLAMINE;6-CHLOROCHROMAN-4-AMINE

Molecular Formula:C₉H₁₀ClNO

Molecular Weight:183.63500

HS Code:2932999099

Physical and Chemical Properties:

Melting point:N/A

Boiling point:268.9ºC at 760 mmHg

Density:1.25g/cm3

Index of Refraction:1.574

PSA:35.25000

Exact Mass:183.04500

LogP:2.82260

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-amino-6-chlorochroman chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-CHLOROCHROMAN-4-AMINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-CHLOROCHROMANE-4-YLAMINE Use and application,6-CHLOROCHROMANE-4-YLAMINE technical grade,usp/ep/jp grade.

Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 6-chloro-3,4-dihydro-2H-chromen-4-amine manufacturer At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase. 6-chloro-3,4-dihydro-2H-chromen-4-amine supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. 6-chloro-3,4-dihydro-2H-chromen-4-amine vendor Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement. 6-chloro-3,4-dihydro-2H-chromen-4-amine factory At the same time, due to the increase in production costs and environmental protection cost pressures in Europe and the United States, as well as the improvement of process technology, production quality, and registration and certification capabilities of China’s bulk drug manufacturers, bulk drug companies have accelerated their transfer to China, and the bulk drug industry in China has produced Scale continues to increase.